How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline

lexblog.com/lib/CF3DNKHKview recordjson

{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline – Updated May 2, 2025",
    "url": "https://www.lexblog.com/2025/05/05/how-the-u-s-compares-to-europe-on-biosimilar-approvals-and-products-in-the-pipeline-updated-may-2-2025/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-CF3DNKHK",
        "url": "https://www.lexblog.com/lib/CF3DNKHK/"
    },
    "datePublished": "2025-05-05T13:20:59-04:00",
    "dateModified": "2025-05-05T10:44:07-04:00",
    "author": {
        "@type": "Person",
        "name": "Alex Shaver, Aydin H. Harston"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Rothwell Figg"
    },
    "organizationScope": "at-publication",
    "isPartOf": "Biosimilars Law Bulletin",
    "about": "Health Care and Life Sciences",
    "sourceUrl": "https://www.biosimilarsip.com/?p=5776",
    "sourceStability": "may-move"
}